Logo

Innovent's Byvasda (Bevacizumab Biosimilar) Receive NMPA's Approval for Adult Recurrent Glioblastoma

Share this

Innovent's Byvasda (Bevacizumab Biosimilar) Receive NMPA's Approval for Adult Recurrent Glioblastoma

Shots:

  • The NMPA has approved Byvasda for the treatment of adult recurrent Glioblastoma which is the third approved indication of Byvasda in China
  • The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
  • Byvasda is a bevacizumab biosimilar and a recombinant humanized anti-VEGF monoclonal antibody drug. Byvasda has been approved in China for the treatment of NSCLC and mCRC

 ­ Ref: Innovent  | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions